Alefacept is an immunosuppressive drug that is used to treat moderate to severe forms of the skin disease plaque psoriasis. It is marketed in the United States as Amevive, but it is not licensed for use in the European Union. Its manufacturer is Biogen Idec.

Alefacept is a protein that must be given by injection into a muscle or a vein.

Alefacept should not be used in patients with HIV, as it can cause dangerous reductions in CD4 cell counts. This can speed up HIV disease progression or increase complications.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.